DD218373A5 - Verfahren zur herstellung eines resinates einer substituierten carbonsaeure - Google Patents

Verfahren zur herstellung eines resinates einer substituierten carbonsaeure Download PDF

Info

Publication number
DD218373A5
DD218373A5 DD84259312A DD25931284A DD218373A5 DD 218373 A5 DD218373 A5 DD 218373A5 DD 84259312 A DD84259312 A DD 84259312A DD 25931284 A DD25931284 A DD 25931284A DD 218373 A5 DD218373 A5 DD 218373A5
Authority
DD
German Democratic Republic
Prior art keywords
formula
resinate
acid
resin
active ingredient
Prior art date
Application number
DD84259312A
Other languages
German (de)
English (en)
Inventor
Satish C Khanna
Original Assignee
Ciba Geigy Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy Ag filed Critical Ciba Geigy Ag
Publication of DD218373A5 publication Critical patent/DD218373A5/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/40—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F8/00—Chemical modification by after-treatment
    • C08F8/44—Preparation of metal salts or ammonium salts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A61K47/585—Ion exchange resins, e.g. polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DD84259312A 1983-01-12 1984-01-10 Verfahren zur herstellung eines resinates einer substituierten carbonsaeure DD218373A5 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH14783A CH655507B (no) 1983-01-12 1983-01-12

Publications (1)

Publication Number Publication Date
DD218373A5 true DD218373A5 (de) 1985-02-06

Family

ID=4180317

Family Applications (1)

Application Number Title Priority Date Filing Date
DD84259312A DD218373A5 (de) 1983-01-12 1984-01-10 Verfahren zur herstellung eines resinates einer substituierten carbonsaeure

Country Status (41)

Country Link
US (1) US4510128A (no)
EP (1) EP0122219B1 (no)
JP (1) JPS59134759A (no)
KR (1) KR900006747B1 (no)
AR (1) AR240310A1 (no)
AT (2) AT391467B (no)
AU (1) AU570230B2 (no)
BE (1) BE898649A (no)
CA (1) CA1218077A (no)
CH (1) CH655507B (no)
CS (1) CS269954B2 (no)
DD (1) DD218373A5 (no)
DE (2) DE3474152D1 (no)
DK (1) DK166683B1 (no)
DZ (1) DZ593A1 (no)
EG (1) EG16562A (no)
ES (1) ES528770A0 (no)
FI (1) FI82682C (no)
FR (1) FR2542735B1 (no)
GB (1) GB2134529B (no)
GR (1) GR79793B (no)
HK (1) HK90390A (no)
HU (1) HU190750B (no)
IE (1) IE56545B1 (no)
IL (1) IL70660A (no)
IT (1) IT1177501B (no)
LU (1) LU85171A1 (no)
MA (1) MA20000A1 (no)
MC (1) MC1564A1 (no)
MT (1) MTP943B (no)
NL (1) NL8400098A (no)
NO (1) NO162862C (no)
NZ (1) NZ206815A (no)
OA (1) OA07628A (no)
PH (1) PH21795A (no)
PL (1) PL142737B1 (no)
PT (1) PT77932B (no)
RO (1) RO88481A (no)
SE (1) SE457959B (no)
ZA (1) ZA84212B (no)
ZW (1) ZW484A1 (no)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH664085A5 (de) * 1985-02-08 1988-02-15 Ciba Geigy Ag Pharmazeutische praeparate mit analgetischer wirksamkeit, sowie deren herstellung.
ES8604955A1 (es) * 1985-11-08 1986-03-16 Covex Sa Procedimiento para la preparacion de resinatos de la (-) eburnamenina-14-(15h)-ona
GB8730010D0 (en) * 1987-12-23 1988-02-03 Smith Kline French Lab Compounds
AU608114B2 (en) * 1987-12-23 1991-03-21 Smith Kline & French Laboratories Limited Compounds
US5230885A (en) * 1987-12-23 1993-07-27 Smith Kline & French Laboratories Limited Polystyrene anion exchange polymer pharmaceutical composition
CH675537A5 (no) * 1988-03-25 1990-10-15 Ciba Geigy Ag
SE509029C2 (sv) * 1988-08-16 1998-11-30 Ss Pharmaceutical Co Långtidsverkande diklofenak-natriumpreparat
US4960799A (en) * 1988-09-13 1990-10-02 Ciba-Geigy Corporation Stabilized aqueous solutions of pharmaceutically acceptable salts of ortho-(2,6-dichlorophenyl)-aminophenylacetic acid for opthalmic use
ES2054089T3 (es) * 1988-11-10 1994-08-01 Ciba Geigy Ag Formulaciones orales liquidas.
CA2002492A1 (en) * 1988-11-11 1990-05-11 Sandra T. A. Malkowska Pharmaceutical ion exchange resin composition
GB8911719D0 (en) * 1989-05-22 1989-07-05 Smith Kline French Lab Compounds
GB8913699D0 (en) * 1989-06-14 1989-08-02 Smith Kline French Lab Compounds
GB8913700D0 (en) * 1989-06-14 1989-08-02 Smith Kline French Lab Compounds
US5079001A (en) * 1989-11-03 1992-01-07 Ciba-Geigy Corporation Liquid oral formulation of diclofenac
GB8928278D0 (en) * 1989-12-14 1990-02-21 Smith Kline French Lab Compounds
SE9004129D0 (sv) * 1990-12-21 1990-12-21 Pharmacia Lkb Biotech Anion exchanger
EP0592569A1 (en) * 1991-07-03 1994-04-20 Sano Corporation Composition and method for transdermal delivery of diclofenac
DE60232290D1 (de) * 2001-04-09 2009-06-25 Rohm & Haas Kontrollierte Auflösung von Wirkstoffen
US20020176842A1 (en) * 2001-04-09 2002-11-28 Lyn Hughes Extended release of active ingredients
US20030180249A1 (en) * 2002-03-18 2003-09-25 Khanna Satish Chandra Dosage forms for hygroscopic active ingredients
US20050036977A1 (en) * 2003-08-11 2005-02-17 Dilip Gole Taste-masked resinate and preparation thereof
EP1830851A2 (en) * 2004-12-06 2007-09-12 Themis Laboratories Private Limited Rapid disintegrating taste masked compositions and a process for its preparations
RU2435569C2 (ru) * 2006-03-16 2011-12-10 Трис Фарма, Инк. Композиции с модифицированным высвобождением, содержащие комплексы лекарственное вещество - ионообменная смола
US7799347B2 (en) * 2006-09-07 2010-09-21 Chondrex Inc. Endotoxin-adsorbent for the prevention and treatment of autoimmune diseases
EP2352568B1 (en) * 2008-10-02 2017-11-29 University of Pittsburgh - Of the Commonwealth System of Higher Education Administration of an adsorbent polymer for treatment of systemic inflammation
MX2020011961A (es) 2010-03-24 2022-04-19 Jazz Pharmaceuticals Inc Formas de dosis de liberacion controlada para substancias de farmaco de alta dosis, solubles en agua e higroscopicas.
ES2717469T3 (es) 2012-08-15 2019-06-21 Tris Pharma Inc Comprimido masticable de metilfenidato de liberación prolongada
US10398662B1 (en) 2015-02-18 2019-09-03 Jazz Pharma Ireland Limited GHB formulation and method for its manufacture
US11590228B1 (en) 2015-09-08 2023-02-28 Tris Pharma, Inc Extended release amphetamine compositions
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US20180263936A1 (en) 2017-03-17 2018-09-20 Jazz Pharmaceuticals Ireland Limited Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
US11590081B1 (en) 2017-09-24 2023-02-28 Tris Pharma, Inc Extended release amphetamine tablets
CN113395960A (zh) 2018-11-19 2021-09-14 爵士制药爱尔兰有限公司 抗酒精药物制剂
JP2022522270A (ja) 2019-03-01 2022-04-15 フラメル アイルランド リミテッド 食事摂取状態における改善された薬物動態を有するガンマ－ヒドロキシ酪酸塩組成物
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB857193A (en) * 1957-03-14 1960-12-29 Clinical Products Ltd Resin-drug compounds
GB823000A (en) * 1957-10-03 1959-11-04 Clinical Products Ltd Resin-drug compounds
GB869149A (en) * 1958-09-16 1961-05-31 Clinical Products Ltd Liquid pharmaceutical compositions comprising compounds of ion exchange resins and therapeutic substances
US3316282A (en) * 1965-02-08 1967-04-25 Squibb & Sons Inc Anion exchange resin complex of a cycloborate ester of a steroid
FI49600C (fi) * 1967-12-20 1975-08-11 Ciba Geigy Ag Menetelmä substituoitujen fenyylietikkahappojen ja näiden suolojen val mistamiseksi.
CH519476A (de) * 1968-03-30 1972-02-29 Hoechst Ag Verfahren zur Herstellung von Salzen von Acylamino-alkylbenzolsulfonyl-harnstoffen mit Anionenaustauschern
US3926864A (en) * 1971-06-21 1975-12-16 Ionics Ion exchange membranes having a macroporous surface area
GB1423694A (en) * 1973-07-10 1976-02-04 Beecham Group Ltd Pharmaceutical compositions
US4058491A (en) * 1975-02-11 1977-11-15 Plastomedical Sciences, Inc. Cationic hydrogels based on heterocyclic N-vinyl monomers
FR2352547A1 (fr) * 1976-05-25 1977-12-23 Viridis Ets Nouvelle resine anionique a action hypocholesterolemiante, son procede de preparation et compositions therapeutiques la contenant
US4217421A (en) * 1977-06-27 1980-08-12 Rohm And Haas Company Anion exchange resins prepared from crosslinked polystyrenesulfonylchloride
US4380590A (en) * 1978-09-19 1983-04-19 Rohm And Haas Company Emulsion copolymer cation exchange resins
IT1106718B (it) * 1978-12-21 1985-11-18 Alfa Farmaceutici Spa Composizioni a base di resine anioniche salificate farmacologicamente attive
US4207399A (en) * 1979-03-14 1980-06-10 Rohm And Haas Company Methylquinoline high polymer based on quaternary ammonium polymers
US4302548A (en) * 1980-05-22 1981-11-24 Rohm And Haas Company Production of ion exchange resins, the resins so produced and ion exchange processes using them

Also Published As

Publication number Publication date
ATE37378T1 (de) 1988-10-15
MA20000A1 (fr) 1984-10-01
ZW484A1 (en) 1984-08-08
MTP943B (en) 1984-06-05
ZA84212B (en) 1984-08-29
CS269954B2 (en) 1990-05-14
NO162862C (no) 1990-02-28
GB2134529B (en) 1986-09-24
AT391467B (de) 1990-10-10
DE3400491A1 (de) 1984-07-12
DK11884A (da) 1984-07-13
NL8400098A (nl) 1984-08-01
NZ206815A (en) 1986-08-08
GB2134529A (en) 1984-08-15
MC1564A1 (fr) 1984-11-12
AU570230B2 (en) 1988-03-10
FI82682B (fi) 1990-12-31
ES8504849A1 (es) 1985-05-01
FR2542735B1 (fr) 1986-04-18
DE3400491C2 (no) 1988-11-10
HU190750B (en) 1986-10-28
PT77932B (en) 1986-07-22
DK11884D0 (da) 1984-01-11
KR840007562A (ko) 1984-12-08
AR240310A1 (es) 1990-03-30
EP0122219B1 (de) 1988-09-21
US4510128A (en) 1985-04-09
IL70660A (en) 1987-08-31
IE840049L (en) 1984-07-12
PL245656A1 (en) 1985-01-02
JPS59134759A (ja) 1984-08-02
KR900006747B1 (ko) 1990-09-20
HK90390A (en) 1990-11-09
EP0122219A2 (de) 1984-10-17
IE56545B1 (en) 1991-08-28
FI840069A (fi) 1984-07-13
DE3474152D1 (en) 1988-10-27
BE898649A (fr) 1984-07-11
GR79793B (no) 1984-10-31
ES528770A0 (es) 1985-05-01
HUT34151A (en) 1985-02-28
JPH0257058B2 (no) 1990-12-03
NO162862B (no) 1989-11-20
FI82682C (fi) 1991-04-10
FR2542735A1 (fr) 1984-09-21
NO840090L (no) 1984-07-13
PT77932A (en) 1984-02-01
SE8400098D0 (sv) 1984-01-10
IT8447527A0 (it) 1984-01-10
ATA784A (de) 1990-04-15
OA07628A (fr) 1985-05-23
SE8400098L (sv) 1984-07-13
AU2323084A (en) 1984-07-19
PH21795A (en) 1988-02-29
DZ593A1 (fr) 2004-09-13
IT1177501B (it) 1987-08-26
GB8400251D0 (en) 1984-02-08
EP0122219A3 (en) 1985-05-08
FI840069A0 (fi) 1984-01-09
DK166683B1 (da) 1993-06-28
CA1218077A (en) 1987-02-17
IL70660A0 (en) 1984-04-30
PL142737B1 (en) 1987-11-30
RO88481A (ro) 1986-01-30
LU85171A1 (de) 1984-10-24
CH655507B (no) 1986-04-30
EG16562A (en) 1991-12-30
CS17884A2 (en) 1989-10-13
SE457959B (sv) 1989-02-13

Similar Documents

Publication Publication Date Title
DD218373A5 (de) Verfahren zur herstellung eines resinates einer substituierten carbonsaeure
DE3852781T2 (de) Präparat mit verzögerter Freisetzung sowie dessen Herstellung.
DE68922894T2 (de) Pharmazeutische Ionenaustauscherharzzusammensetzung.
EP0720473B1 (de) Budesonid-pellets mit kontrolliertem freigabeprofil und verfahren zu ihrer herstellung
DE3783163T2 (de) Arzneimittelzubereitungen mit verzoegerter freisetzung.
CH640727A5 (en) Tablet or other solid, compressed article
DE2246037A1 (de) Peroral anwendbares arzneimittel mit verstaerkter resorptionsverzoegerung
DE1520921A1 (de) Verfahren zur Herstellung von Harzsalzen
CH658188A5 (de) Lagerstabile schnellzerfallende pharmazeutische presslinge.
EP0250648B1 (de) Pharmazeutisches Präparat zur verzögerten Freigabe von Ibuprofen
DE10254412A1 (de) Arzneimittel
DE69306243T2 (de) Zusammensetzungen mit verzögerter wirkstoffabgabe
EP0665830B1 (de) Tilidin-dihydrogenorthophosphat, verfahren zu dessen herstellung und dieses enthaltende pharmazeutische zubereitungen
DE3019032A1 (de) Antacider wirkstoff auf magnesium-aluminiumhydroxid-basis, verfahren zu dessen herstellung und dessen verwendung bei der bekaempfung von magenerkrankungen und der hyperaziditaet
DE2259646A1 (de) Hochdosierte tabletten von cephalosporin-derivaten sowie verfahren zu ihrer herstellung
DE1045599B (de) Verfahren zur Herstellung per os applizierbarer, protrahiert wirksamer Aminzubereitungen
DE69103724T2 (de) Pharmazeutische zusammensetzungen mit verzögerter freisetzung zur oralen verabreichung sowie deren herstellungsverfahren.
DE1944694B2 (de) Pharmazeutische zubereitung
EP0253293B1 (de) Neue Guanidiniumasparaginate
DE69100053T2 (de) Arzneimittelzusammensetzung in stabiler wässriger Suspensionsform auf der Basis von Sucralfat und einem Antacidum sowie Verfahren zu ihrer Herstellung.
AT347039B (de) Verfahren zur herstellung von tabletten und dragees mit einem gehalt an zwei verschiedenen heilmittelwirkstoffen mit verzoegerter wirk- stoffabgabe
DE2621906C2 (no)
DD249634A1 (de) Cholesterolsenkendes mittel und verfahren zu seiner herstellung
DE3037598C2 (de) Lysin- und Arginin-Salze der 5-(2,4-Difluorphenyl)-2-hydroxybenzoesäure, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
EP0136502A2 (de) Verwendung von Eisen(II)-, Zink- und Magnesiumsalzen und ihren Mischsalzen zur Substitution von Eisen, Zink und Magnesium

Legal Events

Date Code Title Description
ENJ Ceased due to non-payment of renewal fee